Top 8 Vaccination and Vaccine development startups in USA
Nov 19, 2025
|
Like
22
1
Funding: $3.9B
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
2
Funding: $765M
VBI Vaccines is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
VBI Vaccines is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
3
Funding: $377.5M
Affinivax is a biotechnology company developing technology to provide broad protection against diseases affecting children.
Affinivax is a biotechnology company developing technology to provide broad protection against diseases affecting children.
4
Funding: $196M
Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.
Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.
5
Funding: $100M
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization dedicated to accelerating the product development timeline for diseases that disproportionately affect the world’s poorest populations, starting with malaria, tuberculosis, and diarrheal diseases—diseases that combined cause five deaths every minute.*
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization dedicated to accelerating the product development timeline for diseases that disproportionately affect the world’s poorest populations, starting with malaria, tuberculosis, and diarrheal diseases—diseases that combined cause five deaths every minute.*
6
Funding: $73M
kernal biologics is mRNA vaccine and therapeutics company. It develops onco-selective mRNA immunotherapy
kernal biologics is mRNA vaccine and therapeutics company. It develops onco-selective mRNA immunotherapy
7
Funding: $65.6M
Codagenix employs a proprietary technology platform for the construction of live attenuated viral vaccines for flu and other targets.
Codagenix employs a proprietary technology platform for the construction of live attenuated viral vaccines for flu and other targets.
8
Funding: $11.4M
CaroGen Corporation is an immunotherapy company employing a virus-like vesicle (VLV) platform technology. CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
CaroGen Corporation is an immunotherapy company employing a virus-like vesicle (VLV) platform technology. CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
★
See also:
